New findings support the company’s neuroscience-driven approach to precision psychiatry, offering actionable insights for personalized depression treatment
PALO ALTO, Calif., Jan. 10, 2025 /PRNewswire/ — Universal Brain, a pioneering technology company focused on transforming mental healthcare through neuroscience, today announced the publication of its latest peer-reviewed study, “Neurotyping depression using multiple event-related potentials (ERPs): Leveraging task-based variation to predict remission in depression,” the paper introduces a novel framework for detecting unique neurophysiological patterns that can help predict which depressed patients are most likely to achieve remission from depression.
“By combining several EEG paradigms with novel statistical analyses, we’re moving closer to a future where depression therapies can be precisely tailored to each individual,” said Kazu Okuda, Chief Executive Officer of Universal Brain. “In particular, we are poised to leverage a battery of EEG paradigms to better subtype depression – which will pave the way for more precision in treatment development and selection. These functional measures of brain activity (i.e., neurotypes) will be used to determine what treatment works best for whom.”
Key Highlights of the Study
“This work is especially exciting because it bridges the gap between laboratory-based assessments and potential real-world clinical practice. We believe our new method can help physicians potentially select treatment but also help clinicians fine-tune therapeutic interventions to an individual’s unique neural signature,” commented Greg Hajcak, Chief Scientific Advisor of Universal Brain. “By leveraging multiple ERPs in varying tasks, we can aim to better predict who will respond to specific treatments, a key step in transforming how we approach depression management.”
Championing Precision Psychiatry
Universal Brain’s overarching mission is to integrate cutting-edge neuroscience with clinical insights to advance precision psychiatry—a transformative model of care that personalizes interventions based on individual biological, behavioral, and environmental factors. This focus resonates with emerging trends in psychiatric research to enhance treatment outcomes.
In close collaboration with academic institutions, research hospitals, and clinical partners, Universal Brain continues to drive neuroscience-based innovation that bridges the gap between academic discoveries and real-world patient care.
For more information on Universal Brain’s research and the company’s commitment to developing neuroscience-driven solutions for mental health, please visit universal-brain.com or email us at media@universal-brain.com.
About Universal Brain
Universal Brain is a science-driven technology company dedicated to revolutionizing mental healthcare by unlocking the power of precision psychiatry. Drawing on advances in neuroscience, data analytics, and engineering, Universal Brain develops innovative tools and platforms that personalize psychiatric treatment and improve patient outcomes. To learn more, visit www.universal-brain.com.
SOURCE Universal Brain
Partnership will leverage Iktos's AI-enabled drug discovery platform and Cube Biotech's advanced protein technologies to…
SurVaxM is the first drug product to be produced in UI Pharmaceuticals new facilityUI Pharmaceuticals…
LAS VEGAS, Jan. 10, 2025 /PRNewswire/ -- RingConn, a leading smart wearable brand, is proud…
VANCOUVER, BC / ACCESSWIRE / January 10, 2025 / 1933 Industries Inc. (the "Company" or…
Montreal, Quebec--(Newsfile Corp. - January 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF)…
These products address critical challenges in accessing and analyzing real-world data while advancing precision medicine…